Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김상헌 | - |
dc.date.accessioned | 2019-07-02T06:11:03Z | - |
dc.date.available | 2019-07-02T06:11:03Z | - |
dc.date.issued | 2019-01 | - |
dc.identifier.citation | ALLERGY ASTHMA & IMMUNOLOGY RESEARCH, v. 11, NO 1, Page. 43-54 | en_US |
dc.identifier.issn | 2092-7355 | - |
dc.identifier.issn | 2092-7363 | - |
dc.identifier.uri | https://synapse.koreamed.org/DOIx.php?id=10.4168/aair.2019.11.1.43 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/107036 | - |
dc.description.abstract | Purpose Although mild to moderate asthma is much more common, the morbidity and mortality of severe asthma are much higher. This study was performed to identify and analyze the clinical characteristics of severe asthma in Korea. Methods We registered patients with severe refractory asthma into the Severe Asthma Registry supported by the Severe Asthma Work Group of the Korean Academy of Asthma, Allergy and Clinical Immunology. Patients were enrolled since 2010 from the 15 university hospitals nationwide in Korea. Severe asthma was defined according to modified European Respiratory Society/American Thoracic Society criteria. Information on demographics, medical history, pulmonary function tests and skin prick tests was collected; the clinical characteristics of severe asthmatics were analyzed from the collected data. Results A total of 489 patients were enrolled with a mean age of 62.3; 45% are male. Sixty percent of patients received Global Initiative for Asthma step 4 treatment, and 30% received step 5 treatment. The most common comorbidities were allergic rhinitis (58.7%). Aspirin hypersensitivity was observed in 14.0%. Approximately half (53.9%) are non-smokers. Atopy was proven in 38.5% of the patients. Regarding asthma medications, inhaled corticosteroids and long-acting β-agonist combination inhalers were most commonly prescribed (96.5%), followed by leukotriene antagonists (71.0%). A recombinant anti-immunoglobulin E monoclonal antibody (omalizumab) has been used in 1.8% of the patients. The mean forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and FEV1/FVC were 78.7%, 67.5% and 67.9% of predicted values, respectively. The mean Asthma Control Test and quality of life questionnaire scores were 16.5 out of 25 and 59.5 out of 85, respectively. Conclusions The baseline characteristics of severe asthma patients in the Korea Severe Asthma Registry were analyzed and reported for the first time. With this cohort, further prospective studies should be performed to search for ways to improve management of severe refractory asthma. | en_US |
dc.description.sponsorship | This study was supported by a grant from the Korean Academy of Asthma, Allergy and Clinical Immunology. | en_US |
dc.language.iso | en | en_US |
dc.publisher | KOREAN ACAD ASTHMA ALLERGY & CLINICAL IMMUNOLOGY | en_US |
dc.subject | Asthma | en_US |
dc.subject | severe asthma | en_US |
dc.subject | registry | en_US |
dc.title | Characteristics of Adult Severe Refractory Asthma in Korea Analyzed From the Severe Asthma Registry | en_US |
dc.type | Article | en_US |
dc.relation.no | 1 | - |
dc.relation.volume | 11 | - |
dc.identifier.doi | 10.4168/aair.2019.11.1.43 | - |
dc.relation.page | 43-54 | - |
dc.relation.journal | ALLERGY ASTHMA & IMMUNOLOGY RESEARCH | - |
dc.contributor.googleauthor | Kim, Min-Hye | - |
dc.contributor.googleauthor | Kim, Sang-Heon | - |
dc.contributor.googleauthor | Park, So-Young | - |
dc.contributor.googleauthor | Ban, Ga-Young | - |
dc.contributor.googleauthor | Kim, Joo-Hee | - |
dc.contributor.googleauthor | Jung, Jae-Woo | - |
dc.contributor.googleauthor | Moon, Ji Yong | - |
dc.contributor.googleauthor | Song, Woo-Jung | - |
dc.contributor.googleauthor | Kwon, Hyouk-Soo | - |
dc.contributor.googleauthor | Kwon, Jae-Woo | - |
dc.relation.code | 2019040260 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | sangheonkim | - |
dc.identifier.orcid | https://orcid.org/0000-0001-8398-4444 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.